UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38266 SPERO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorpora ...

Spero Therapeutics, Inc. (NASDAQ:SPRO) Q4 2023 Earnings Conference Call March 13, 2024 4:30 PM ET Company Participants Michael Wood - Managing Director of LifeSci Advisors Sath Shukla - CEO Kamal Hamed - CMO Esther Rajavelu - CFO and Chief Business Officer Conference Call Participants Ritu Baral - TD Cowen Louise Chen - Cantor Operator Good afternoon and welcome to the Spero Therapeutics Full Year 2023 Financial Results Conference Call. At this time, all participants are in a listen-only mode. Following the ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____to____ Commission file number 001-38266 SPERO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 46-4590683 State or other juri ...

Spero Therapeutics, Inc. (NASDAQ:SPRO) Q3 2023 Earnings Conference Call November 13, 2023 4:30 PM ET Company Participants Ted Jenkins - Vice President, Investor Relations and Strategic Finance Sath Shukla - Chief Executive Officer Kamal Hamed - Chief Medical Officer Steve Dipalma - Interim Chief Financial Officer and Treasurer Conference Call Participants Louise Chen - Cantor Fitzgerald Boobalan Pachaiyappan - H.C. Wainwright Good afternoon and welcome to the Spero Therapeutics Third Quarter 2023 Financial ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38266 SPERO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) | Delaware | 46-4590683 | | --- | --- ...

Spero Therapeutics, Inc. (NASDAQ:SPRO) Q2 2023 Earnings Conference Call August 10, 2023 4:30 PM ET Company Participants Ted Jenkins - Vice President, Investor Relations and Strategic Finance Sath Shukla - Chief Executive Officer Kamal Hamed - Chief Medical Officer Steve Dipalma - Interim Chief Financial Officer and Treasurer Conference Call Participants Louise Chen - Cantor Boobalan Pachaiyappan - H.C. Wainwright Ritu Baral - Cowen Operator Good afternoon and welcome to the Spero Therapeutics Second Quarter ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38266 SPERO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) | Delaware | 46-4590683 | | --- | --- | | ...

Spero Therapeutics, Inc. (NASDAQ:SPRO) Q1 2023 Earnings Conference Call May 11, 2023 4:30 PM ET Company Participants Ted Jenkins – Vice President, Investor Relations and Strategic Finance Ankit Mahadevia – Chief Executive Officer Sath Shukla – Chief financial Officer Kamal Hamed – Chief Medical Officer Conference Call Participants Louise Chen – Cantor Ritu Baral – TD Cowen Gavin Clark-Gartner – Evercore ISI Boobalan Pachaiyappan – H.C. Wainwright Operator Good afternoon, and welcome to the Spero Therapeutic ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38266 SPERO THERAPEUTICS, INC. (Registrant's telephone number, including area code) Securities registered pursuant to Section 1 ...

Spero Therapeutics, Inc. (NASDAQ:SPRO) Q4 2022 Earnings Conference Call March 30, 2023 4:30 PM ET Company Participants Ted Jenkins - VP & Head, IR Ankit Mahadevia - Co-Founder, President, CEO & Director Kamal Hamed - Chief Medical Officer Satyavrat Shukla - CFO & Treasurer Conference Call Participants Louise Chen - Cantor Fitzgerald & Co. Operator Good afternoon, and welcome to Spero Therapeutics Fourth Quarter and Year-End 2022 Financial Results Conference Call. [Operator Instructions]. Please be advised t ...